In the Claims

1. (currently amended) A method for treating ~~or preventing~~ infection of feline immunodeficiency virus (FIV) in a feline animal, said method comprising administering to said feline animal an effective amount of azidothymidine (AZT) and ~~another~~ the nucleoside analog 3TC, and wherein said feline animal receives bone marrow transplantation after total body irradiation.

Claims 2-3 (canceled)

4. (previously amended) The method according to claim 1, wherein the transplanted cells are selected from the group consisting of allogeneic cells and autologous cells.

5. (currently amended) A method for treating ~~or preventing~~ infection of feline immunodeficiency virus (FIV) in a feline animal, said method comprising administering to said feline animal an effective amount of azidothymidine (AZT), ~~another~~ the nucleoside analog 3TC and an inhibitor of a retroviral protease, and wherein said feline animal receives bone marrow transplantation after total body irradiation.

Claim 6 (canceled)

7. (original) The method according to claim 5, wherein said inhibitor of a retroviral protease is selected from the group consisting of HIV protease inhibitors and FIV protease inhibitors.

8. (previously amended) The method according to claim 5, wherein said inhibitor of a retroviral protease is designated as HBY-793 and has the structure shown in Figure 4.

Claims 9-10 (canceled)

11. (previously amended) The method according to claim 5, wherein the transplanted cells are selected from the group consisting of allogeneic cells and autologous cells.

Claims 12-15 (canceled)

16. (currently amended) The method according to claim 1, wherein said azidothymidine or said ~~another~~ nucleoside analog 3TC is administered as an oral or nasal formulation.

17. (previously added) The method according to claim 1, wherein said azidothymidine or said nucleoside analog is administered by intravenous, intramuscular, or subcutaneous injection.

18. (previously added) The method according to claim 1, wherein said azidothymidine or said nucleoside analog is administered in a dosage form selected from the group consisting of tablet, pill, powder, liquid solution or suspension, liposome, suppository, injectable, and infusible solution.

19. (currently amended) The method according to claim 1, wherein said FIV is a strain of FIV selected from the group consisting of FIV_{Pet}, FIV_{Dix}, ~~FIV_{UK-8}~~ FIV_{UK8}, FIV_{Bang}, FIV_{Aom1}, FIV_{Aom2}, and FIV_{Shi}.

20. (currently amended) The method according to claim 5, wherein said azidothymidine, said ~~another~~ nucleoside analog 3TC, or said retroviral protease inhibitor is administered as an oral or nasal formulation.

21. (currently amended) The method according to claim 5, wherein said azidothymidine, said ~~another~~ nucleoside analog 3TC, or said retroviral protease inhibitor is administered by intravenous, intramuscular, or subcutaneous injection.

22. (currently amended) The method according to claim 5, wherein said azidothymidine, said ~~another~~ nucleoside analog 3TC, or said retroviral protease inhibitor is administered in a dosage form

selected from the group consisting of tablet, pill, powder, liquid solution or suspension, liposome, suppository, injectable, and infusible solution.

23. (currently amended) The method according to claim 5, wherein said FIV is a strain of FIV selected from the group consisting of FIV_{Pet}, FIV_{Dix}, ~~FIV_{UK-8}~~ FIV_{UK8}, FIV_{Bang}, FIV_{Aom1}, FIV_{Aom2}, and FIV_{Shi}.